Loading market dashboard
Agilent Technologies, Inc.
AHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Agilent Technologies, Inc. (A) Presents at Jefferies Global Healthcare Conference 2026 Transcript
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company's products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment.
Examine Agilent's (A) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
A beat Q2 estimates and raised its fiscal 2026 outlook. It says its Ignite operating system is driving more durable gains in pricing, execution and margins.
The healthcare solutions specialist is also on track to top analyst estimates for the full year. The company saw growth in several key client segments.
U.S. stocks were higher, with the Nasdaq Composite gaining around 200 points on Thursday.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent's OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As.
Agilent Technologies, Inc. (A) Q2 2026 Earnings Call Transcript
Agilent Technologies NYSE: A raised its fiscal 2026 outlook after reporting stronger-than-expected second-quarter results, with management pointing to broad-based demand, instrument replacement momentum, pricing actions and operational gains from its Ignite operating system.
The headline numbers for Agilent (A) give insight into how the company performed in the quarter ended April 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Agilent Technologies (A) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.4 per share. This compares to earnings of $1.31 per share a year ago.
Life sciences firm Agilent Technologies raised its 2026 adjusted profit forecast on Wednesday, anticipating strong demand for its medical tools and equipment used in lab research and diagnostic services.
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. Second-quarter GAAP net income was $339 million, or $1.20 per share. This compares with $215 million, or $0.75 per share, in the second quarter of 2025. Non-GAAP net income(3) was $423 million, or $1.49 per share, during the quarter, compar.
Agilent Technologies Inc. (NYSE: A) today announced the release of a new [url="]multi-attribute method (MAM)[/url] workflow designed to help pharmaceutical and
Agilent Technologies Inc. (NYSE: A) today announced the launch of the new [url="]8890B GC[/url] and [url="]8860B GC[/url] with GC Assist. GC Assist is the new,
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of a new multi-attribute method (MAM) workflow designed to help pharmaceutical and biopharmaceutical quality control (QC) laboratories implement liquid chromatography high-resolution mass spectrometry (LC/HRMS) in routine, regulated testing environments. The Agilent MAM solution brings together software, instrumentation, columns, consumables and standards to address practical and operational ba.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the new 8890B GC and 8860B GC with GC Assist. GC Assist is the new, advanced instrument intelligence that provides system monitoring, built-in troubleshooting, and remote connectivity to analytical instrumentation within the laboratory's secure network. These systems enable higher performance and productivity across gas chromatography analyses. The new systems are designed to help laboratorie.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent 9500 Triple Quadrupole ICP-MS, a next-generation inductively coupled plasma mass spectrometry system designed to help single quadrupole ICP-MS laboratories more easily transition to triple quadrupole technology for advanced trace elemental analysis. As testing demands grow more complex and skilled resources remain limited, laboratories face increasing pressure to deliver faster, i.
Evaluate the expected performance of Agilent (A) for the quarter ended April 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent 1290 Infinity III Fluorescence Detector (FLD), a new fluorescence detector designed specifically for modern ultra-high-performance liquid chromatography (UHPLC) workflows. The detector extends fluorescence detection into the UHPLC era by combining ultra-trace sensitivity, UHPLC-ready chromatographic performance, and routine-ready ease of use. Designed for use as a standalone detec.
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on July 22, 2026, to all shareholders of record as of the close of business on June 30, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analytica.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has been awarded a contract by the Transportation Security Administration (TSA) and will deploy its new Bulk Alarm Resolution Technology (BRT) to security checkpoints at FIFA World Cup U.S. host city airports with the capabilities to screen larger quantities of liquids, powders, and solids commonly encountered in airport security screening operations. “Agilent is thrilled to have been selected by T.
Agilent (A) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for 9:20 EDT on Wednesday, June 3, 2026, in New York City. A live audio webcast and replay of the presentation will be available through Agilent's Investor Relations website. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global lead.
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced the appointment of Michael Buckner as chief legal officer, effective today. Buckner brings nearly three decades of experience as a senior global legal executive, with a proven track record of building and leading high-performing teams and deep expertise in complex transactions and regulatory environments. “We are thrilled to welcome Michael to the Agilent team,” said Padraig McDonnell, Agilent president an.
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2026 after the stock market closes on Wednesday, May 27. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call will also be available on the website for 90 days. Abo.
Arizona State Retirement System lowered its stake in shares of Agilent Technologies, Inc. (NYSE: A) by 7.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,796 shares of the medical research company's stock after selling 6,132 shares during the
Calamos Advisors LLC reduced its stake in shares of Agilent Technologies, Inc. (NYSE: A) by 3.9% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 163,570 shares of the medical research company's stock after selling 6,642 shares during the period. Calamos
Boston Trust Walden Corp trimmed its holdings in shares of Agilent Technologies, Inc. (NYSE: A) by 9.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 207,881 shares of the medical research company's stock after selling 21,880 shares during the quarter. Boston
ATLANTA--(BUSINESS WIRE)--Axion BioSystems, Inc., a leading provider of live-cell analysis technologies, today announced that Agilent Technologies, Inc. and Axion BioSystems have fully resolved the issues in the two lawsuits between them, pending in the United States District Court for the District of Delaware, pursuant to the terms of a confidential settlement agreement. Neither party has admitted liability for the other party's claims or counterclaims or otherwise agreed to the positions asse.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand f.
Assetmark Inc. increased its holdings in Agilent Technologies, Inc. (NYSE: A) by 5.9% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 234,275 shares of the medical research company's stock after buying an additional 12,984 shares during the period. Assetmark
CCLA Investment Management grew its holdings in shares of Agilent Technologies, Inc. (NYSE: A) by 1.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,047,488 shares of the medical research company's stock after purchasing an additional 19,518 shares
Agilent Technologies, Inc. (NYSE: A - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen research firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to
Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in Agilent Technologies, Inc. (NYSE: A) by 288.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,463 shares of the medical research company's stock after acquiring an additional 9,258
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea.
Agilent (A) reported earnings 30 days ago. What's next for the stock?
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica.
Nordea Investment Management AB lessened its stake in Agilent Technologies, Inc. (NYSE: A) by 5.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,774,119 shares of the medical research company's stock after selling 106,321 shares during the period. Nordea Investment Management AB
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a founda.
Danske Bank A S bought a new position in shares of Agilent Technologies, Inc. (NYSE: A) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 401,467 shares of the medical research company's stock, valued at approximately $51,528,000. Danske Bank A S owned approximately
Agilent Technologies, Inc. (A) Shareholder/Analyst Call Prepared Remarks Transcript
Aquatic Capital Management LLC reduced its position in Agilent Technologies, Inc. (NYSE: A) by 43.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 53,601 shares of the medical research company's stock after selling 41,359 shares during the period. Aquatic Capital Management LLC's holdings in
Citi swept through its life science tools and diagnostics coverage on Wednesday, opening a 90-day upside catalyst watch on Agilent Technologies ( NYSE:A ) while trimming its price target on Icon PLC ( NASDAQ:ICLR ) following a turbulent earnings season for the sector.
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company's expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing so.
Life sciences firm Agilent Technologies said on Monday that it will acquire clinical pathology firm Biocare Medical in an all-cash deal valued at $950 million.
Denver, CO and London, UK, 9 March 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, GHO Capital Partners LLP (“GHO”), a specialist investor in global healthcare, and Biocare Medical (“Biocare”), a global leader of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, today announce that Biocare has entered into an agreement to be acquired by Agilent Technologies (“Agilent”, NYSE:A), a prominent player in life sciences, diagnostics, and applied chemical markets.
SANTA CLARA, Calif. & SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in sit.
